Skip to content

TherapeuticsMD: FDA IDs deficiencies in review

April 10, 2017

*Therapeuticsmd provides tx-004hr regulatory update

* Therapeuticsmd Inc – on April 7, received a letter from fda

* Therapeuticsmd-FDA says as part of review of tx-004hr nda, has identified deficiencies preclude discussion of labeling, postmarketing requirements/at this time

* Therapeuticsmd inc – letter states that notification does not reflect a final decision on information under review

* Therapeuticsmd Inc – letter does not specify deficiencies identified by FDA and at this time company is not aware of nature of deficiencies

* Therapeuticsmd Inc – intends to work with fda to understand nature of deficiencies and resolve them as quickly as possible


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: